Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

Morrison Foerster Recognized as a Leading Life Sciences Practice by LMG Life Sciences

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Community

Offices

Careers

Stay Connected

Morrison Foerster was ranked as a leading firm in the 2025 edition of LMG Life Sciences, with 16 MoFo lawyers achieving...

<h3>Sorry, we weren’t able to find the terms you entered.</h3>Please try a different term or keyword.

People

Capabilities

Resources

Not Found Cards

About Morrison Foerster

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison Foerster was ranked as a leading firm in the 2025 edition of LMG Life Sciences, with 16 MoFo lawyers achieving recognition for their individual achievements. LMG Life Sciences ranks firms and individuals based on case evidence and client and peer feedback.Morrison Foerster’s market-leading life sciences team was highlighted as a Tier 1 practice for Patent Strategy & Management and as a Tier 2 practice for both Patent Prosecution and General Patent Litigation.The following MoFo lawyers were recognized as Life Sciences Stars:<ul><li>Adam Brausa - General Patent Litigation</li><li>Bindu Donovan - General Patent Litigation, Hatch-Waxman Patent Litigation</li><li>Brian Kramer - General Patent Litigation</li><li>Brian Matsui - General Patent Litigation</li><li>Brigid Bondoc - FDA: Medical Device, FDA: Pharmaceutical</li><li>Catherine M Polizzi - Patent Prosecution, Patent Strategy & Management</li><li>Daralyn Durie - General Patent Litigation</li><li>Deanne Maynard - General Patent Litigation</li><li>Janet Xiao - Patent Prosecution</li><li>Jim Krenn - Mergers & Acquisitions, Venture Capital</li><li>Jonathan Bockman - Patent Strategy & Management</li><li>Karen Potter - Patent Prosecution, Patent Strategy & Management</li><li>Kira A Davis - General Patent Litigation</li><li>Michael Ward - Patent Prosecution, Patent Strategy & Management</li><li>Todd Krause - Hatch-Waxman Patent Litigation</li><li>Shannon Reaney - Patent Prosecution, Patent Strategy & Management</li></ul>LMG Life Sciences is the only legal ranking directory to identify the leading law firms and individuals in each practice area of the life sciences industry through in-depth analysis of the business and legal developments in the sector.To view the complete list of Morrison Foerster’s rankings in the 2025 edition of LMG Life Sciences, please visit the publication’s <a href="https://lmglifesciences.com/Firm/Morrison-Foerster-United-States/Rankings/1237#rankings" target="_blank">website</a>.

Morrison Foerster Recognized as a Leading Life Sciences Practice by LMG Life Sciences

Sign Up

Brigid is a food, drug, and medical device lawyer who counsels life sciences companies on a wide range of U.S. Food & Drug Administration pre- and post-market regulatory issues.As the lead of our FDA + Healthcare Regulatory and Compliance Group, Brigid practices across the spectrum of FDA-regulated products, including medical devices, drugs, biologics, cell and gene therapies, food, cosmetics, dietary supplements, tobacco, laboratory-developed tests, in vitro diagnostics, radiation-emitting electronic products, combination products, and products that may not fit neatly into any of these categories. Accordingly, she counsels established and start-up companies in life sciences, healthcare, and consumer products on a wide range of FDA pre- and post-market regulatory issues. Brigid also frequently advises innovative product developers on threshold FDA jurisdictional questions and develops strategies for approval and marketing, while identifying and mitigating regulatory risks.In her day-to-day practice, Brigid advises on:<ul><li>product development and FDA’s pre-authorization requirements;</li><li>advertising and promotion of FDA-regulated products;</li><li>clinical trials regulation, including strategic advice for sponsors in receipt of a clinical hold;</li><li>responses to warning letters, Form 483s, import alerts, and FDA enforcement actions;</li><li>informal and formal dispute resolution for high-stakes issues;</li><li>compliance with FDA regulatory requirements such as current good manufacturing practice (GMP), quality system regulation (QSR), food safety preventive controls, adverse event reports, product recalls, radiological health issues, risk evaluation and mitigation strategies (REMS), pharmacy compounding and the new track-and-trace regulations for prescription drugs; and</li><li>technical legal questions involving the Food, Drug and Cosmetic Act (FDCA), the Public Health Service Act (PHSA), Federal Advisory Committee Act (FACA), Freedom of Information Act (FOIA), and the Administrative Procedure Act (APA).</li></ul>Brigid also has experience in the development, regulation, and procurement of medical countermeasures (MCMs) against chemical, biological, radiological, and nuclear (CBRN) threats and pandemic infectious diseases, including animal rule approvals and special incentives for the development of MCMs.Complementing her focus on FDA regulatory law, Brigid has a strong litigation background and has served as FDA counsel in product liability cases, civil litigation, international arbitration, and FDA enforcement proceedings. She particularly enjoys providing clients with advice that integrates technical, legal, and political considerations.Brigid maintains an active pro bono practice focused primarily on reproductive health and especially enjoys working with inventors who aim to improve health outcomes for mothers and infants in the peri- and post-natal period. She has represented several clients before the Social Security Administration in appealing denials of applications for disability benefits. She has also worked on several appeals in criminal cases in the District of Columbia.Brigid is a graduate of the University of Tulsa, where she earned her B.S. in biochemistry before attending law school at Stanford Law School. Prior to law school, Brigid worked as an Environmental Policy Analyst in the Office of the Secretary at the U.S. Department of Transportation. She has also worked as a benchtop scientist in a number of laboratories, including FDA’s National Center for Toxicological Research.<h4>Representative Experience</h4><ul><li>Counseled online marketplaces regarding FDA compliance and enforcement for a variety of products.</li><li>Advised development-stage companies on regulatory considerations and FDA engagement strategies related to development and launch of products based on disruptive technologies.</li><li>Advised consumer technology companies with respect to potential FDA regulation under the medical device provisions of the FDCA;</li><li>Served as FDA regulatory counsel to clients evaluating compliance issues under reporting provisions of Corporate Integrity Agreements and related negotiated resolutions of government investigations.</li><li>Helped a large, publicly traded drug company comply with the FDA’s new track-and-trace pedigree requirements for prescription drugs.</li><li>Led regulatory team on numerous initial public offerings (IPO), stock and asset purchase agreements, acquisitions, mergers, and other transactions for life science company.</li><li>Provided strategic advice, conducting regulatory assessments and negotiating key FDA-related terms in connection with due diligence for transactions and post-acquisition integration activities.</li><li>Developed policy positions related to FDA regulation of laboratory-developed tests (LDTs) for multiple clients in this space.</li><li>Represented manufacturers in matters involving regulatory letters, inquiries, advisory comment proceedings, competitor complaints and citizen petitions focused on their products and policy issues affecting their strategic priorities.</li><li>Advised on issues related to promotion of drugs and medical devices, including communication of pharmacoeconomic/healthcare economic information (HCEI), communications by medical science liaisons (MSLs).</li><li>Provided solutions-oriented advice to development-stage companies confronting FDA regulatory issues for the first time, including good clinical practices (GCP), investigator-initiated research (IIR), pre-approval communications and strategies for obtaining FDA approval.</li><li>Collaboratively advised client on FDA, ethical, and product liability issues associated with early termination of a clinical study involving an implanted medical device.</li></ul>

Brigid Bondoc

Partner

Jon Bockman is the head of the firm’s Technology Patent Practice. In this capacity, he leads the firm’s prominent group of patent practitioners with degrees in electrical engineering, mechanical engineering, computer science, computer engineering, chemical engineering, biomedical engineering and physics. His team handles work in all technology areas including medical devices, AI and machine learning, cybersecurity, computer hardware, advanced materials, and robotics. His practice concentrates on domestic and international patent prosecution, portfolio management, IP due diligence, patent infringement and validity determinations, and IP litigation support. His clients range from some of the largest domestic and international companies to early-stage startups.As lead patent prosecution counsel for several large and emerging companies, Jon has helped clients set up patent departments and committees for building and maintaining strategic patent portfolios. Clients note to IAM Patent 1000 that “[Jon] provides expert legal advice that is clear, understandable and tailored to the needs of the specific client. He is very responsive and is always available when you need him.”Jon has extensive experience helping clients navigate IP concerns including freedom-to-operate and potential litigation issues. Jon is also experienced with leading patent due diligence projects related to investments and mergers and acquisitions. He often leads investor-side and company-side patent due diligence reviews related to these transactions.Jon is a member of the firm’s Inter Partes Review and Post Grant Practice. In this capacity, he handles inter partes review and post-grant review proceedings that were introduced by the Leahy-Smith America Invents Act. He has also handled many disputes for clients in front of the U.S. Patent and Trademark Office (USPTO), including inter partes reexaminations, ex parte reexaminations, and derivation proceedings.Jon is recognized as an IP Star by Managing Intellectual Property and as a leading patent practitioner by IAM Patent 1000. He is also recommended by The Legal 500 US for patent prosecution. While earning his J.D., Jon was the associate editor of the University of Colorado Law Review.

Jonathan Bockman

Adam is a trial lawyer, who focuses his practice on patent litigation. Adam’s clients look to him as lead counsel in district court litigation, post-grant proceedings at the Patent Office, and at the Federal Circuit. With every client, Adam starts by listening and learning about their business, so that he and his team can craft a bespoke legal strategy best suited to accomplish his client’s goals.Adam represents numerous Fortune 500 companies including Genentech, Shopify, Squarespace, and GoPro, as well as emerging and venture-funded companies across industry sectors. He was part of the team that led enforcement of Genentech’s Cabilly family of patents, which generated billions of dollars in licensing revenue, and also represented Genentech in some of the earliest litigations relating to biosimilar legislation. For his client Itron Networked Solutions, Inc., Adam led the team that succeeded in invalidating both asserted patents in IPR proceedings and then successfully defended the Board’s final written decisions at the Federal Circuit.As a result of Adam’s work, he has been recognized by numerous industry publications as a top life sciences litigator. Most recently, Adam was named a Litigation Star for 2023 by Benchmark Litigation.In addition to his patent litigation practice, Adam maintains an active pro bono practice, with a particular focus on foster care dependency proceedings. He also serves on the Board of FamilyBuilders, a nonprofit foster family and adoption agency in the Bay Area.Adam holds a B.S. from Northwestern University in chemical engineering and worked as an engineer at Proctor & Gamble before attending law school. Adam earned his J.D. cum laude from Northwestern Law School, where he served on the Northwestern University Law Review.

Adam Brausa

Kira is an experienced courtroom lawyer who assists life sciences companies in high-stakes patent litigation.Kira is the head of Morrison Foerster’s Los Angeles Litigation Department, a partner in the IP Litigation Group, and a member of the firm-wide Life Sciences + Healthcare Leadership Team. She regularly serves as counsel in intellectual property lawsuits involving cutting-edge technology, including foundational antibody technology, antibody cancer immunotherapies, fusion proteins, small-molecule therapeutics, transcatheter heart valve repair and replacement devices, and genetic testing and genomics technology. Kira litigates on behalf of both patentees and defendants and has significant experience representing innovators in disputes arising out of proposed generic and biosimilar launches.    Kira has been recognized by a number of regional and national publications, including as a Litigator of the Week by The American Lawyer. In 2023, she was named a Top Healthcare Lawyer by the Daily Journal.   Kira’s approach is to gain a deep understanding not only of the technology at issue, but also of her clients’ business objectives and goals, and to work closely with her clients to build litigation and pre-litigation strategies that match those goals. As a trial lawyer, Kira is known for her levelheaded and trustworthy style, allowing client witnesses to shine through on direct examination and cutting through the noise on cross-examination.In addition to U.S. district court litigation, Kira regularly advises clients on proceedings before the Patent Trial and Appeal Board, both in matters with co-pending litigation and in stand-alone PTAB proceedings. She also often coordinates global patent litigation strategy across multiple jurisdictions, including England, Ireland, Germany, and Switzerland.Kira also has experience representing clients in connection with other types of litigation and investigative matters, including antitrust litigation, contract disputes, white-collar criminal matters, complex commercial disputes, sports-related matters, and internal investigations.Kira began her legal career as a law clerk to the Honorable John M. Rogers in the United States Court of Appeals for the Sixth Circuit. Prior to joining the firm, Kira was a partner at Durie Tangri, a premier litigation boutique.Kira received her J.D. summa cum laude from Cornell Law School. She received her B.A. in classics from Ohio Wesleyan University.She is admitted to practice in California and New York.

Kira Davis

Bindu Donovan has been litigating high-stakes intellectual property disputes in the life sciences field for over 25 years.Bindu, a seasoned partner in Morrison Foerster’s Intellectual Property Litigation group specializes in patent litigation in U.S. federal district courts. She has a broad range of experience in life sciences, representing clients in matters related to biologic and small-molecule drugs, medical devices, recombinant proteins, and vaccines. Her extensive portfolio extends to representing innovator companies in Hatch-Waxman cases covering treatments for ADHD, diabetes, influenza, hypertension, and metastatic prostate cancer, including blockbuster drugs.Bindu excels in leading large litigation teams in all aspects of complex patent infringement disputes, including pre-suit investigations, pre-trial and expert discovery, trial preparation, and trial. She is adept at coordinating global strategies for her clients’ most important products. Additionally, her experience includes breach of contract and trade secret disputes, mediation, and arbitration.Bindu has been consistently recognized as a leading practitioner in her field. LMG Life Sciences acknowledged her contributions to life sciences-related patent work, and IAM Patent 1000 ranked her as a Leading IP Litigation Lawyer. Additional notable accolades include being named one of the Top 250 Women in Litigation and a Local Litigation Star by Benchmark Litigation. Managing Intellectual Property also named her an “IP Star” and one of the Top 250 Women in IP.Bindu serves on the board of managers of the New Jersey Intellectual Property Law Association (NJIPLA) and participates in various other legal organizations.<h4>Representative Experience</h4><ul><li>Represented international biopharmaceutical company in confidential matter involving offensive and defensive patent assertion strategy concerning vaccines.</li><li>Represented international biopharmaceutical company in confidential pre-suit investigation relating to fusion protein.</li><li>Represented VMI Holland BV in breach of contract action.</li><li>Represented patent holder Johnson & Johnson subsidiary, Actelion Pharmaceuticals Ltd., in patent infringement suits filed under the Hatch-Waxman Act involving pulmonary arterial hypertension drug Tracleer®.</li><li>Represented patent holder Avanos in patent infringement suit involving cooled radiofrequency ablation products.</li><li>Represented patent holder Johnson & Johnson subsidiary, Janssen, in patent infringement suits filed under the Hatch-Waxman Act and inter partes review proceedings involving prostate cancer drug, Zytiga®.</li><li>Represented patent holders Gilead and Roche/Genentech in patent infringement suit filed under the Hatch-Waxman Act involving influenza drug, Tamiflu®.</li><li>Represented patent holders Cordis Corporation and Wyeth in patent infringement suits involving drug eluting stents.</li><li>Represented defendant Johnson & Johnson in patent infringement suit involving sunscreen compositions.</li><li>Represented a pharmaceutical company in a patent infringement lawsuit filed under the Hatch-Waxman Act involving a medication for ADHD.</li><li>Represented patent holder SmithKline Beecham in patent infringement suit filed under the Hatch-Waxman Act involving Type 2 diabetes drug, Avandia®.</li></ul>

Bindu Donovan

Daralyn Durie is among the top trial lawyers in the country, acting as go-to trial counsel for both plaintiffs and defendants. Daralyn’s exceptional track record has earned her consistent recognition from leading national publications. Chambers has listed her among the top 10 intellectual property lawyers in the U.S. and Law360 has recognized her as an “Icon of IP” and an MVP. Benchmark Litigation reported that “going against her was like going against a boxer in which you know you’re going to get hurt.” She’s a fellow in the American College of Trial Lawyers, a member of the American Board of Trial Advocates, and an inductee into the California Trial Lawyer Hall of Fame.Daralyn’s legal career began at Berkeley Law, followed by a clerkship for the Honorable Douglas Ginsburg on the U.S. Court of Appeals for the District of Columbia Circuit. She became a partner at a litigation boutique in 1999 and, in 2009, co-founded Durie Tangri, a premier litigation boutique that later combined with Morrison Foerster in 2023.In addition to her courtroom successes, Daralyn is actively involved in the legal community. She is a board member of the National Women’s Law Center, a past president of the Northern California Association of Business Trial Lawyers, and served as an adjunct professor at Berkeley Law, where she taught civil trial advocacy.Life SciencesDaralyn has decades of experience in the life sciences sector. She spearheaded the enforcement of Genentech’s Cabilly family of patents, which generated billions of dollars in licensing revenue. She served as lead counsel in the Herceptin biosimilar litigation and recently achieved a plaintiff-side jury verdict of $178 million in a patent infringement case involving melanoma therapy.TechnologyIn the tech sector, Daralyn recently won defense jury verdicts for Aptiv (USB hubs), Activision (in the Eastern District of Texas), and Redbubble. She served as lead counsel for Google, defending Google Books from copyright infringement claims. Following extensive litigation on copyright and antitrust issues, Google prevailed on summary judgment, resulting in Daralyn being named an Attorney of the Year by California Lawyer magazine.

Daralyn Durie

Brian is a trial lawyer focusing primarily on patent litigation, often defending companies accused of patent infringement. His work spans diverse technology areas, such as pharmaceuticals, medical devices, diagnostic tools, and DNA sequencing techniques. He has also represented makers of ultracapacitors, video compression techniques, and wireless technology.Brian has successfully tried cases in U.S. district courts and successfully argued appeals before the U.S. Court of Appeals for the Federal Circuit. His trial experience includes obtaining a jury verdict of non–infringement for a client sued by a rival for over $100 million, and a bench trial involving a drug with annual sales over $4 billion.Brian is a member of the American Intellectual Property Law Association, Federal Circuit Bar Association, and American Bar Association. He is chair of the board of directors of the Japan Society of San Diego and Tijuana, and past president of the board of directors of the Legal Aid Society of San Diego.In law school, he served as an associate editor of the University of Illinois Law Review and as the first managing editor of the University of Illinois Journal of Law, Technology & Policy.

Brian M. Kramer

Todd Krause is a partner and member of the firm’s Intellectual Property Litigation Group. Todd has over 25 years of experience successfully litigating patent cases for leading global pharmaceutical and biotechnology companies.To help his clients succeed, Todd clearly defines their strategic objectives, develops compelling trial themes early in the case, focuses his teams on issues that truly matter, and distills complex issues down to clear, factfinder-friendly trial arguments. With a Ph.D. in biological sciences and a postdoctoral fellowship in the Department of Molecular and Human Genetics at Baylor College of Medicine, Todd brings a profound understanding of the scientific aspects of his cases.Todd has guided teams in numerous Hatch-Waxman litigations (most involving blockbuster drugs) and a diverse range of matters in the life sciences industry, including small-molecule and biologic drugs, medical devices, gene amplification techniques, cell-based assays, veterinary vaccines, and recombinant nucleic acids and proteins.Recognized as a leading figure in the patent and life sciences legal fields, Todd has earned accolades such as being named as a Hatch-Waxman Patent Litigation Star by LMG Life Sciences; named as an IP Star by Managing Intellectual Property; and recommended by the IAM Patent 1000 and The Legal 500. He remains actively involved in legal organizations, while contributing to the advancement of his clients’ industries.<h4>Representative Experience</h4><ul><li>Represented multinational biopharmaceutical company in patent litigation related to a treatment for an autoimmune disease.</li><li>Represented global biopharmaceutical company in patent litigation related to a HIV treatment.</li><li>Represented Avanos in patent litigation related to cooled radiofrequency ablation products.</li><li>Represented Johnson & Johnson subsidiary Janssen Biotech, Inc. in Hatch-Waxman patent litigations and inter partes review proceedings related to prostate cancer drug Zytiga®.</li><li>Represented Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. in Hatch-Waxman patent litigations related to the blood-thinner Xarelto®.</li><li>Represented international pharmaceutical company in patent litigation related to cancer immunotherapy.</li><li>Represented global biopharmaceutical company in patent litigation involving genetic mutations, recombinant DNA and proteins, and cellular assays related to a brain disorder.</li><li>Represented Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc. in Hatch-Waxman patent litigation related to Nucynta®, a drug for the treatment of pain.</li><li>Represented Forest Laboratories Inc. in multidistrict Hatch-Waxman patent litigations involving the blood pressure reduction agent Bystolic®.</li><li>Represented Sunovion Pharmaceuticals, Inc. in Hatch-Waxman patent litigation involving Xopenex HFA®, an inhalation aerosol used to treat the narrowing of airways by asthma and chronic obstructive pulmonary disease.</li><li>Represented Schering Corporation and MSP Singapore (both now owned by Merck) in several Hatch-Waxman patent litigations involving the blockbuster cholesterol lowering drugs Vytorin® and Zetia®.</li><li>Represented ConvaTec, Inc. in a patent action involving negative pressure wound healing devices.</li><li>Represented Columbia University professor, Dr. Gertrude Rothschild in patent actions related to methods for making semiconductor materials.</li><li>Represented Mycogen Corp. in patent action arising under 35 U.S.C. §291 of the patent laws that involved genetically modified plants.</li><li>Represented Boehringer Ingelheim in patent litigations related to a veterinary vaccine.</li><li>Represented Hoffmann-La Roche in patent litigation related to the Nobel Prize winning technology Polymerase Chain Reaction (“PCR”) and a polymerase (“Taq”) used in that technology.</li><li>Represented Hoffmann-La Roche and Boehringer Ingelheim in patent litigations related to the use of cell-based assays for drug discovery.</li></ul>

Todd Krause

Jim Krenn is a corporate partner and chair of the firm’s Emerging Companies + Venture Capital Group.Jim has comprehensive experience representing emerging, growth-stage, and public companies, as well as angel, corporate, and institutional investors, in strategic transactions and corporate matters throughout the company lifecycle, from formation and early-stage financings through liquidity events and public company operations. Jim’s practice focuses on mergers and acquisitions, financings, and general corporate counseling, with a particular emphasis on life science and technology companies. He regularly advises boards of directors, executive teams, and investors on complex transactional matters, capital-raising activities, and corporate governance issues.In his mergers and acquisitions practice, Jim represents buyers and sellers in domestic and cross-border transactions across a wide range of structures, including mergers, stock and asset purchases, divestitures, joint ventures, and competitive sale processes. He has represented clients in acquisitions and sales ranging from the low millions to transactions exceeding $1 billion, for both private and public companies.Jim also counsels venture-backed and growth-stage companies in equity financings and ongoing corporate matters, and advises leading angel, corporate, and venture capital investors in their investments in such companies. He has represented clients in hundreds of venture capital and growth equity financings, from seed and early-stage rounds through $100 million-plus later-stage rounds.In addition, Jim represents public companies in initial public offerings, other capital markets transactions, and SEC reporting and compliance matters, and advises boards of directors on corporate governance issues. Jim is a member of the firm’s Life Sciences + Healthcare Group leadership team and Artificial Intelligence steering committee. He is actively involved in the startup and venture capital ecosystem, including  serving on the Board of Directors of the San Diego Entrepreneurs Exchange.<h4>Representative Transactions</h4><h5>Mergers and Acquisitions</h5><ul><li>ACEA Biosciences, a medical instruments company, in its sale to Agilent Technologies (NYSE: A) for $250 million.</li><li>Adicet Bio (Nasdaq: ACET), a biopharmaceutical company, in its merger with a wholly owned subsidiary of resTORbio (Nasdaq: TORC) to create a combined publicly traded biotechnology company.</li><li>Alaska Energy & Resources Company, a parent company of a regulated electric utility in Alaska, in its $170 million sale to Avista (NYSE: AVA).</li><li>Astute Medical, a medical diagnostic company, in its $90 million sale to bioMérieux (EPA: BIM).</li><li>B. Riley Financial (Nasdaq: RILY), a diversified financial services company, in its $53 million private placement and merger with investment banking firm B. Riley & Co.</li><li>Biotix, a private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions, in its sale to Mettler-Toledo (NYSE: MTD).</li><li>California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple acquisitions.</li><li>Clean Energy Fuels (Nasdaq: CLNE), a provider of natural gas as an alternative fuel for vehicle fleets, in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP).</li><li>Cogent (Nasdaq: COGT), a biometric identification solutions provider, in its $943 million sale to 3M (NYSE: MMM).</li><li>Deere & Company (NYSE: DE), an agricultural, construction, and forestry machinery corporation, in its planned acquisition of the precision planting unit of Monsanto (NYSE: MON).</li><li>Dosatron International, a distributor of water-powered dosing pumps and systems, in connection with its sale to Ingersoll Rand (NYSE:IR).</li><li>Gillco, a leading specialty ingredient provider, in its sale to Azelis (BR: AZE).</li><li>Mentor (NYSE: MNT), a leading supplier of medical products for the global aesthetic market, in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).</li><li>Mitchell International, a developer of smart technology solutions, in its acquisition of Cogent Works.</li><li>MyChem, a provider of ultra-pure nucleotides, in connection with its sale to Maravai (NASDAQ: MRVI) for $240 million at closing with potential additional consideration.</li><li>Protomer Technologies, a biotechnology company, in its sale to Eli Lilly and Company (NYSE: LLY) with a potential value of over $1 billion with successful achievement of future development and commercial milestones.</li><li>Rakuten Medical, a biotechnology and medical device company, in its acquisition of Medlight SA and its acquisition of key assets and manufacturing technology from Li-Cor Biosciences.</li><li>Safebuilt Insurance Services, a managing general agent and insurance technology company, in its sale to Integrated Specialty Coverages.</li><li>Sequlite Genomics, a DNA sequencing firm, in connection with its sale to Fapon Biotech, a diagnostic technology company.</li><li>Tendo, a digital health software company, in its acquisition of MDsave, a healthcare marketplace company.</li><li>Wavestream, a provider of high-power solid-state amplifiers, in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (Nasdaq: GILT).</li></ul><h5>Equity Financings</h5><ul><li>9amHealth, a provider of virtual diabetes care, in its $4 million Series Seed financing and $16 million Series A financing.</li><li>ACEA Biosciences, a developer of cell analysis instrumentation technologies, in its $30 million Series E Preferred Stock financing.</li><li>Adicet Bio, a biopharmaceutical company, in its Series A financing of up to $51 million, and $80 million Series B financing.</li><li>Astute Medical, a medical diagnostic company focused on high-risk medical conditions and diseases, in over $200 million of equity and debt financings.</li><li>Bidra as an investor in multiple equity financings.</li><li>Biolumic, an agtech company, in its $13.5 million Series B financing.</li><li>California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple equity and debt financings.</li><li>Carlsmed, a medtech company pioneering AI-enabled personalized spine surgery solutions, in its $10 million Series A financing, $30 million Series B financing, $64.5 million Series C financing and $100.5 million initial public offering.</li><li>Corner Therapeutics, a biotech company, in its $54 million Series A financing.</li><li>Crinetics (Nasdaq:CRNX) as a strategic investor in Radionetics Oncology’s $52.5 million Series A financing.</li><li>Crinetics(Nasdaq:CRNX) in its $350 million PIPE financing, at-the-marketing offering of up to $350 million, $575 million underwritten public offering and $350 million underwritten public offering.</li><li>Forward Ventures as an investor in multiple equity financings, convertible debt financings, and M&A transactions.</li><li>Foxen, a provider of financial technology solutions for the real estate industry, in its $44 million Series A financing.</li><li>Greenoaks Capital Partners and its affiliates as investors in multiple equity financings, debt financings, and secondary transactions.</li><li>GroupSolver, an artificial intelligence market research platform, in multiple preferred stock financings.</li><li>Hume.ai, an artificial intelligence company, in multiple preferred stock financings.</li><li>Oak Investment Partners as an investor in multiple preferred stock financings.</li><li>OrbiMed as an investor in multiple equity financings, debt financings, and M&A transactions.</li><li>Petuum, an artificial intelligence and machine learning software infrastructure provider, in its $93 million Series B financing.</li><li>Pi Health, an AI-enabled health technology and clinical research company, in its spin-out from BeiGene, Ltd. and $35 million Series A financing.</li><li>Perceptive Advisors as an investor in multiple financings and transactions.</li><li>Presight Capital as an investor in multiple equity financings.</li><li>RA Capital as an investor in multiple equity financings.</li><li>Rakuten Medical, a biotechnology and medical device company, in over $800 million of debt and equity financings.</li><li>Rubi Laboratories, a company focused on converting carbon emissions into textiles, in multiple equity financings.</li><li>Softbank affiliates as investors in multiple equity financings.</li><li>Solarflare Communications, a technology company, in over $200 million of equity and debt financings.</li><li>Tendo Systems, a HealthTech software company, in its $20 million financing from Vistara.</li><li>Tutor Intelligence, an artificial intelligence robotics company, in its $34 million Series A financing.</li><li>VoloAgri, an ag-tech company, in over $150 million of equity financings.</li><li>Western Digital Capital as an investor in multiple preferred stock financings.</li></ul>

Jim Krenn

Co-Chair of Emerging Companies + Venture Capital Practice

Brian Matsui co-chairs Morrison Foerster’s Appellate and Supreme Court practice. Brian is a go-to appellate advocate for sophisticated clients in complex appeals.Brian has a nationwide appellate practice. He has argued many cases in federal and state appellate courts throughout the country, winning appeals involving commercial disputes, securities litigation and enforcement, government contracts, consumer class actions, and intellectual property. He has led appeals in the D.C., Second, Fourth, Fifth, Ninth, Eleventh, and Federal Circuits. His arguments include significant victories in class action appeals and in appeals for leading financial services companies, with multiple victories in the Ninth Circuit, where he clerked. Brian recently has gone six for seven when representing appellants, including a precedential victory in the Ninth Circuit in a licensing dispute concerning alleged patent misuse. He also argued and won a D.C. Circuit appeal against the Securities and Exchange Commission (SEC) about the retroactivity of part of the Dodd-Frank Act. As a result of Brian’s win, the SEC had to change its enforcement practices against certain securities industry professionals.Clients frequently turn to Brian for his substantial experience with appeals in the Federal Circuit, praising him as “an invaluable advocate in patent matters” (Chambers USA). Brian has won 14 of his last 16 appeals in that Court. His arguments before the Federal Circuit include winning appeals from district courts, the Patent Trial and Appeal Board, and the International Trade Commission. He has handled appeals in a myriad of industries, including mobile devices, pharmaceuticals, medical devices, semiconductors, and software.Brian also plays a key role on trial teams, advising clients on both critical legal issues and appellate preservation. He recently argued and prevailed against a summary judgment invalidity motion in a case involving Chugai Pharmaceutical Co. Ltd.’s revolutionary antibody recycling technology, which ultimately led to a $775 million settlement on the eve of trial for Chugai.A former law clerk for the United States Supreme Court, Brian has authored many briefs in that Court, including on important constitutional and statutory interpretation issues. He often represents clients’ interests in amicus briefs in significant Supreme Court cases affecting the business community.Leading publications have recognized Brian for his appellate skills. The Legal 500 US recommends him for appellate litigation, and the National Law Journal named Brian a “Minority 40 Under 40.”Brian also dedicates significant time to pro bono matters. He argued and won two significant appeals—in the Second and Ninth Circuits—obtaining reversals of judgments that had denied private rights of action under the Child Welfare Act in precedential decisions. Brian also led the Morrison Foerster team who co-counseled a successful Eighth Amendment challenge to Florida’s imposition of a “life without the possibility of parole” sentence to a juvenile offender convicted of a non-homicide crime.For years, Brian chaired the ABA’s seven-person Standing Committee for Amicus Curiae Briefs. He served on the American Intellectual Property Law Association’s amicus committee and co-chaired the National Asian Pacific American Bar Association’s amicus committee. Brian served as an appellate lawyer representative for the Ninth Circuit. Brian also serves on the board of directors for the Lawyers’ Committee for Civil Rights Under Law.Before entering private practice, Brian clerked on the United States Supreme Court for Justice Anthony M. Kennedy. He also clerked for Judge Pamela Ann Rymer in the Ninth Circuit and Judge David F. Levi in the Eastern District of California.While in law school, Brian served as managing editor of Volume 51 of the Stanford Law Review and was elected to the Order of the Coif.<h4>Representative Oral Arguments</h4><ul><li><a href="https://oralarguments.cafc.uscourts.gov/default.aspx?fl=22-1260_02102023.mp3" target="_blank">SNIPR Technologies Ltd. v. Rockefeller University</a> (Fed. Cir.). Prevailed in a precedential decision reversing the Patent Office's interpretation of the America Invents Act (AIA) that subjected patents post-dating the Act to pre-AIA interference proceedings. The decision revived five of SNIPR’s patents related to CRISPR technology</li><li><a href="/resources/video-audio/220114-broadcom-corporation-v-renesas-matsui" target="_self">Renesas Electronics Corporation v. Broadcom Corporation</a> (12:40) (Fed. Cir.). Successfully argued and briefed multiple appeals from an International Trade Commission (ITC) decision and several Patent Trial and Appeal Board decisions related to an ITC investigation initiated by Broadcom involving systems-on-chip powering automobile infotainment systems</li><li><a href="/resources/video-audio/210706-cr-bard-v-medline-industries" target="_self">C.R. Bard Inc. v. Medline Industries, Inc.</a> (0:45) (Fed. Cir.). Won vacatur of three Patent Trial and Appeal Board decisions on obviousness</li><li><a href="https://oralarguments.cafc.uscourts.gov/default.aspx?fl=21-1745_03102022.mp3" target="_blank">Advanced Voice Recognition Systems, Inc. v. Apple Inc.</a> (14:30) (Fed. Cir.). Secured a complete victory in appeal from Patent Trial and Appeal Board that all challenged patent claims were unpatentable</li><li><a href="/resources/video-audio/200515-william-paulus-v-ocera-therapeutics-inc" target="_self">William Paulus v. Ocera Therapeutics, Inc.</a> (13:25) (9th Cir.). Successfully argued and briefed appeal in a putative shareholder class action involving a tender offer</li><li><a href="/resources/video-audio/200410-kurtz-v-costco" target="_self">Kurtz v. Costco Wholesale Corporation </a>(9:23) (2d Cir.). Successfully petitioned for review of a class certification decision, then argued and obtained a remand for the district court to reconsider its certification decision, and an eventual reversal on an injunctive class certification decision</li><li><a href="/resources/video-audio/161117-gregory-bartko-v-sec" target="_self">Gregory Bartko v. SEC</a> (0:53) (D.C. Cir.). Successfully argued and obtained precedential ruling that the Securities and Exchange Commission could not retroactively apply Dodd-Frank’s industry-wide sanctions on securities professionals for certain securities violations</li></ul>

Brian Matsui

Deanne Maynard, a partner in Morrison Foerster’s Appellate and Supreme Court practice, is widely recognized as one of the nation’s leading appellate advocates. She has argued 14 cases before the United States Supreme Court and 75 times in appellate courts across the country.In ranking Deanne in Band 1, Chambers USA reports that she is described as a “magnificent and top-notch lawyer” who is “wicked smart.” She is “extremely thoughtful, even-keeled and has a wonderful presence in the courtroom.” Legal 500 calls Deanne “one of the finest advocates in the Supreme Court bar,” remarking that “if she is on your team, great. If she’s on the other side, be ready.”Deanne’s winning Supreme Court arguments involve a wide range of issues and industries, including life sciences (Sandoz v. Amgen), intellectual property (MedImmune v. Genentech), antitrust (Pacific Bell v. linkLine), financial services (Ransom v. FIA Card Services), and bankruptcy (RadLAX v. Amalgamated Bank). In Sandoz v. Amgen, the Supreme Court ruled for her client in a closely watched case involving the Biologics Price Competition and Innovation Act, which provides an approval path for biosimilars. Law360 named Deanne to its exclusive list of <a href="http://media2.mofo.com/documents/171212-mvp-deanne-maynard.pdf" target="_blank">Appellate MVPs</a> for this “big victory,” dubbing her a “Legal Lion” three separate times for her work on appeals in this case. LMG Life Sciences also named Deanne <a href="/resources/news/190920-deanne-maynard-appellate-litigator-of-the-year" target="_self">Appellate Litigator of the Year</a>.Deanne argues complex, high stakes cases in courts of appeals nationwide. Clients turn to Deanne for crisp, clear briefs and exceptional oral advocacy. Her appellate wins run a gamut of issues from arbitration to antitrust, class actions to contracts, copyright to Commerce Clause, infringement to invalidity, and securities law to statutory interpretation. Clients praise her as “an incredible oral advocate, very prepared and formidable” (Chambers USA), and “a tireless advocate with sterling client skills” (Legal 500).Deanne has particular experience in the Federal and Ninth Circuits. She has argued more than 40 appeals in the Federal Circuit, including wins for both patentees and defendants on a wide range of technologies. Chambers USA ranked Deanne in Band 1 for Intellectual Property Appeals, describing her as “renowned for her track record in bet-the-company disputes.” She also serves as Chair of the Federal Circuit’s Advisory Council, which is a conduit between the Court and the public. In the Ninth Circuit, her many wins include a decision from the en banc Court holding large parts of a California statute unconstitutional as well as a panel decision vacating a $60 million jury verdict.Deanne is annually recommended as a leading lawyer by Chambers USA, Chambers Global, Legal 500 US, and Best Lawyers in America. She is President of the American Academy of Appellate Lawyers, an invitation-only organization recognizing distinguished appellate lawyers. Deanne is also a Master in, and Past President of, the Coke Appellate Inn of Court.Deanne is a leader within Morrison Foerster as well, chairing its partner compensation committee and serving on the firm’s leadership team.Before joining the firm, Deanne served as an Assistant to the Solicitor General at the U.S. Department of Justice for five years. She previously was a partner at another major law firm.After law school, Deanne clerked two Terms on the United States Supreme Court, one for Justice Stephen Breyer and another for Justice Lewis Powell (Ret.) and Justice John Paul Stevens. Before that, Deanne clerked two years for Judge Stanley Harris on the U.S. District Court for the District of Columbia.Deanne graduated magna cum laude from Harvard Law School, where she was an editor of the Harvard Law Review. She earned a B.A. in English, with distinction, from the University of Virginia.<h4>Supreme Court Arguments</h4><ul><li><a href="/resources/video-audio/170426-sandoz-v-amgen" target="_self">Sandoz v. Amgen</a> (00:17): Involving the Supreme Court’s first foray into the Biologics Price Competition and Innovation Act</li><li><a href="/resources/video-audio/120423-radlax-v-amalgamated-bank" target="_self">RadLAX v. Amalgamated Bank</a> (25:46): Whether a debtor can sell a secured asset free and clear without permitting the lienholder to credit-bid</li><li><a href="/resources/video-audio/081208-pacific-bell-v-linkline" target="_self">Pacific Bell v. linkLine</a> (18:38): Whether Section 2 of the Sherman Antitrust Act permits a price squeeze claim in the absence of a duty to deal</li><li><a href="/resources/video-audio/061004-medimmune-v-genentech" target="_self">MedImmune v. Genentech</a> (17:38): Whether a patent licensee must breach a license agreement before seeking a declaration of patent invalidity</li><li><a href="/resources/video-audio/101004-ransom-v-fia-card-services" target="_self">Ransom v. FIA Card Services</a> (26:34): Involving when a debtor without lease payments may take a car-ownership deduction</li><li>EC Term of Years Trust v. U.S.: Whether the federal tax code relegates a trust to a wrongful levy action as its exclusive remedy</li><li>Marshall v. Marshall: Involving the scope of the probate exception to federal jurisdiction</li><li>U.S. v. Olson: Involving the federal government’s sovereign immunity under the Federal Tort Claims Act</li><li>Wilkinson v. Austin: Whether the procedures governing placement of prisoners in supermax prison satisfied due process</li><li>Greenlaw v. U.S.: Involving the power of the court of appeals in the absence of a cross-appeal</li><li>Dean v. U.S.: Whether the accidental discharge of a firearm during a robbery results in a mandatory minimum prison term</li><li>Carcieri v. Salazar: Involving the Secretary of the Interior’s authority to take land into trust for Indians</li><li>Boulware v. U.S.: Whether a profitless corporation’s diversion of funds to a shareholder was nontaxable</li><li>Watson v. U.S.: Whether trading drugs for a firearm was “using” a firearm “during and in relation” to a drug trafficking crime</li></ul><h4>Representative Appellate Arguments</h4><ul><li><a href="/resources/video-audio/210903-in-re-cirba" target="_self">In re Cirba</a> (25:53) (Fed. Cir.): Successfully defeated attempt to revive a jury’s patent infringement verdict against VMware</li><li><a href="/resources/video-audio/170426-phigenix-v-genentech" target="_self">Phigenix v. Genentech </a>(11:21) (Fed. Cir.): Secured noninfringement judgment for Genentech</li><li><a href="/resources/video-audio/181018-zabriskie-v-fannie-mae" target="_self">Zabriskie v. Fannie Mae</a> <a href="http://youtu.be/Cz_Hp0VIkYs">(Video)</a> (0:00) (9th Cir.): Won reversal for Fannie Mae of a Fair Credit Reporting Act judgment</li><li><a href="/resources/video-audio/161108-washington-university-v-wisconsin-alumni" target="_self">Washington University v. Wisconsin Alumni Research Foundation</a> (0:42) (3d Cir.): Obtained reversal for Washington University in suit for royalties due under contract with WARF</li><li><a href="/resources/video-audio/191202-nevro-v-boston-scientific" target="_self">Nevro v. Boston Scientific</a> (00:10) (Fed. Cir.): Won reversal of district court judgment of invalidity for indefiniteness</li><li><a href="/resources/video-audio/180514-aviation-v-huerta" target="_self">National Business Aviation Assoc. v. Huerta</a> (28:34) (D.C. Cir.): Successfully defended the City of Santa Monica against a challenge to its settlement with the FAA about its municipal airport</li><li><a href="/resources/video-audio/200601-cr-bard-v-angiodynamics" target="_self">C.R. Bard v. Angiodynamics</a> (00:29) (Fed. Cir.): Won reversal of district court judgment of noninfringement, no willfulness, and invalidity, reviving client’s infringement case on three patents</li><li><a href="/resources/video-audio/190409-flores-v-ups" target="_self">Flores v. UPS & Pocino Foods v. UPS (Consolidated)</a> (<a href="http://youtu.be/eas0RAExOME" target="_blank">Video</a>) (13:43) (9th Cir.): Secured judgment for UPS on two putative RICO and breach-of-contract class actions about its Next Day Air services</li><li>Residential Capital v. Federal Housing Finance Agency (2d Cir.): Successfully obtained a remand in a case stemming from the ResCap bankruptcy</li><li><a href="/resources/video-audio/171005-basf-argument" target="_self">BASF v. Johnson Matthey</a> (0:17) (Fed. Cir.): Won reversal of an invalidity ruling against patentee BASF, reviving its patent claims</li><li><a href="/resources/video-audio/190419-holl-v-us-district-court" target="_self">Holl v. U.S. District Court</a> (<a href="https://youtu.be/ilT3hbMCTQ0" target="_blank">Video</a>) (13:32) (9th Cir.): Defeated a mandamus petition against UPS, successfully defending its arbitration provision containing a class-action waiver</li><li>Interactive Digital Software Association v. St. Louis County, Missouri (8th Cir.): Successfully argued a First Amendment challenge to an ordinance regulating video games</li><li>In Re: Tremont Securities Law (2d Cir.): Secured dismissal for a major accounting firm of a putative class action regarding a Madoff-related fund</li><li><a href="/resources/video-audio/141216-estate-of-graham-v-sothebys" target="_self">Estate of Graham v. Sotheby’s</a> (30:46) (9th Cir.) (en banc): Won invalidation under the Commerce Clause of parts of a California artist resale royalty law</li><li><a href="/resources/video-audio/111206-atm-fee-antitrust-litigation" target="_self">In re ATM Fee Antitrust Litigation</a> (17:20) (9th Cir.): Prevailed in a putative nationwide antitrust class action against one of the largest U.S. ATM networks</li><li><a href="/resources/video-audio/131205-augme-technologies-v-yahoo" target="_self">Augme Technologies v. Yahoo!</a> (21:49) (Fed. Cir.): Secured a noninfringement judgment for Yahoo! in a suit involving Internet display advertising</li><li><a href="/resources/video-audio/170830-lummi-nation-argument" target="_self">Lower Elwha Klallam Indian Tribe v. Lummi Nation</a> (<a href="http://youtu.be/OILs47RhSjM" target="_blank">Video</a>) (00:03) (9th Cir.): Won a reversal for the Lummi Nation, reclaiming its historic treaty rights</li><li><a href="/resources/video-audio/141201-warsaw-orthopedic-v-nuvasive" target="_self">Warsaw Orthopedic v. NuVasive</a> (17:44) (Fed. Cir.): Obtained vacatur of a jury’s $101 million patent damages award</li><li><a href="/resources/video-audio/150504-momenta-v-amphastar" target="_self">Momenta v. Amphastar</a> (02:55) (Fed. Cir.): Successfully argued for a patentee that conduct was unprotected by the Hatch-Waxman Act safe harbor</li><li><a href="/resources/video-audio/120605-neurovision-medical-products-v-nuvasive" target="_self">Neurovision Medical Products v. NuVasive</a> (00:00) (9th Cir.): Obtained vacatur of a jury’s $60 million trademark verdict</li></ul>

Deanne E. Maynard

Catherine Polizzi, known as a pioneer in Patent Prosecution + Strategy law, is a deeply experienced lawyer who is highly regarded by clients and competitors alike. Her intellectual versatility combined with incisive, pragmatic counseling and business acumen is the hallmark of her practice. Catherine has the unique experience of working with both startups and emerging companies as well as well‑known, established global companies through the challenging process of obtaining patents and provides strategic, effective portfolio counseling and management, as well as strategic advice surrounding freedom of operation and other forms of IP assessment. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including cancer, cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases such as Alzheimer’s disease.She also has significant experience in a wide spectrum of technology areas, including biologics such as antibodies and polypeptides; nucleic acids; precision medicine including precision oncology; diagnostics; cell therapy including T cell and NK cell technologies, such as chimeric antigen receptors; drug formulation technologies; drug delivery technologies such as nanotechnologies; therapeutic and prophylactic vaccines; microfluidics; drug screening systems; AI solutions for life sciences including drug discovery and development platforms; polynucleotide therapeutics such as siRNA; amplification and detection technologies; genetic screening; sequencing technologies including next-generation sequencing; regenerative medicine; spectroscopy; surgical imaging technologies; and organic chemistry including small molecule drugs.Catherine’s unique background, ability to integrate IP with a given business model to translate into meaningful valuation, risk assessment and advice, and highly effective communication skills in critical settings, such as R&D, all phases of product development, and investment contexts, enable her to provide effective, creative solutions to the significant challenges often faced by clients. Catherine is an acquisition and value enhancement driver as well, a critical conduit for companies as they grow from startup through IPO, exit, and beyond.IP Leadership for Transactions, Financings, and Acquisitions. Catherine’s practice also includes due diligence evaluation and counseling in the context of venture investment assessments and in connection with public and private financing, spin‑offs, partnerships, and mergers and acquisitions, where her IP strategies have helped drive the value of multibillion-dollar deals.Strategist in Legal Challenges and a Key Member of Litigation Teams. In addition to helping create value and commercialize her clients’ technologies, Catherine devises strategies and defenses to fortify their patents in the event of legal challenges by competitors. She renders advice on all aspects of patent positioning, including opinions on patentability, validity, freedom of operation, infringement, and competitor IP evaluation. She also works in the area of third-party challenges, such as inter partes review (IPR) and oppositions.A Recognized Leader. Catherine formerly served as the chair of the firm’s Patent Prosecution & Counseling Group and co-chair of the firm’s Intellectual Property Group. Chambers USA noted that Catherine “maintains a strong reputation for her capabilities advising biotechnology clients on portfolio management and other IP matters,” while clients note that she is “a great strategic thinker, great at flagging the high-level questions and brings a good business perspective” and praise her for “bring[ing] a good business perspective to IP efforts which is not always evident with other IP attorneys.” Catherine has also received many awards and accolades throughout her career, including the following:<ul><li>Ranked in four different Chambers categories for IP and Life Sciences 2011–2025</li><li>Recognized as a Hall of Fame lawyer by LMG Life Sciences for Patent Prosecution and Patent Strategy & Management since 2018</li><li>Recognized as Patent Star by Managing IP for 2025</li><li>Recommended as a leading lawyer by The Legal 500 U.S. for 2012–2024</li><li>Recognized among World’s Leading Patent Practitioners by IAM Patent 1000 for 2014–2024</li><li>Recognized as a Best Lawyer in Biotechnology and Life Sciences by Best Lawyers for 2023 and 2024</li><li>Selected as one of the Top 100 Intellectual Property Lawyers in California by The Daily Journal for 2009–2022</li></ul><h4>Representative Experience</h4><ul><li>Genentech, the world’s first and most successful biotechnology company, has relied on Catherine’s strategic patent counseling and prosecution services for its most difficult and challenging patent matters for nearly 15 years. Her work involves developing overall patent strategy, patent application drafting, and prosecution for key technologies. Her high-value work for Genentech also includes strategic assessment of key and novel technologies, as well as patent litigation support and advisement.</li><li>10x Genomics, a biotechnology company developing forefront gene sequencing technology used in scientific research, turns to Catherine to serve as lead patent counsel related to in situ and spatial assay platforms for cellular and subcellular identification of cell and biomarker diversity in tissues, including gene expression, gene sequencing, RNA profiling, and related reagents, panels, hardware, and software analysis tools.</li><li>Codexis, a biotechnology company that specializes in enzyme engineering, focusing on improving sustainability and cost-efficiency of manufacturing in the pharmaceutical industry, including in the manufacture of oligonucleotides and small molecule drugs, relies on Catherine for developing Codexis’s complex IP strategy. She has provided critical advice in management of their intellectual property portfolio, including strategic consideration of patent application filings, and patent risks to their planned commercial operations, including freedom to operate.</li><li>Juno Therapeutics has relied on Catherine for patent strategy and prosecution from its very beginning. Juno is one of the best-funded startups in biotechnology history. It went on to become a publicly traded company in 2014 and ultimately was acquired by Celgene in 2018 for $9 billion; the strength of the patent portfolio that Catherine crafted helped drive the valuation for the deal. She led the IP team on the acquisition.</li><li>Celgene calls on Catherine for its patent strategy, drafting, and IP due diligence matters. She worked with Abraxis BioScience for many years in a similar capacity to help develop their IP position for the highly successful cancer drug, Abraxane. Catherine then counseled the company through its $2.9 billion acquisition by Celgene Corporation, including providing significant IP strategy and due diligence counseling. This IP platform was a major component of the valuation of the company.</li><li>Dewpoint Therapeutics engaged Catherine to lead its patent strategy from the very beginning. Dewpoint is on the cutting edge of drug discovery, with technology relating to condensate biology, a new and paradigm‑shift area of drug development. Catherine led the IP strategy and due diligence for its partnership with Bayer to research new treatments for cardiovascular and gynecological diseases. The work that Dewpoint is doing is seen as a significant move forward in the biopharma industry and opens the door to many potential new discoveries in biology through biomolecular condensates. For example, in January 2021, Dewpoint teamed up with Pfizer to develop new treatments for a rare kind of muscular dystrophy. In July 2020, Dewpoint announced its collaboration with Merck to evaluate a novel approach for the treatment of HIV.</li><li>Frontier Medicines, a clinical-stage precision medicine company advancing treatments for genetically defined patient populations in oncology and immunology, has entrusted all aspects of patent strategy and portfolio development for its pipeline of small molecule therapeutics to Catherine.</li><li>Insitro, a multibillion-dollar startup pharmaceutical drug company, turned to Catherine to develop its global IP strategy. The company is at the forefront of advancing AI and data-driven drug discovery and development, and trusted Catherine to manage the company’s portfolio.</li><li>Sonoma Biotherapeutics, a clinical-stage biopharmaceutical company that is developing cell therapies that use engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases, called on Catherine to direct its patent strategy and development.</li><li>Additional representative clients include clinical-stage and startup companies, such Aimmune Therapeutics, Alpine Immune Sciences, Botanical Solution, Cartography Biosciences, CohBar, Corner Therapeutics, Cytokinetics, Dynavax Technologies, Enveda Therapeutics, Frazier Life Sciences, GOA Therapeutics, Immunome, Indapta Therapeutics, Larkspur Biosciences, Lyndra Therapeutics, Maze Therapeutics, Myst Therapeutics, Nanoprobes, Ollin Biosciences, Passkey Therapeutics, Prelude Therapeutics, Sana Biotechnology, Sangamo Therapeutics, Seagen (formerly Seattle Genetics), Sirenas, Syntis Bio, Tacit Therapeutics, TARIS Biomedical, The Immune Co., Turnstone Biologics, and Volastra Therapeutics.</li></ul><h5>Aided by Catherine’s leadership and guidance developing IP protection for high-value technology, the following companies were involved in the following high-value transactions:</h5><ul><li>The $4.9 billion cash acquisition of client Alpine Immune Science by Vertex Pharmaceuticals.</li><li>Alpine Immune Sciences’ $48 million Series A financing and subsequent $90 million merger with Nivalis Therapeutics, resulting in a publicly traded company, as well as Alpine Immune Sciences’ $91 million private placement.</li><li>The $2.6 billion acquisition of client Aimmune Therapeutics by Nestlé Health Science.</li><li>The $74 billion acquisition of Celgene Corporation by Bristol Myers Squibb (BMS).</li><li>The $1.1 billion development collaboration with BMS on behalf of Volastra Therapeutics, which was recognized as one of the most promising early-stage biotechnology companies in the industry by Fierce Biotech’s 2022 Fierce 15, to discover, develop, and commercialize new oncology medicines.</li><li>Celgene Corporation’s $9 billion acquisition of client Juno Therapeutics and earlier $2.9 billion acquisition of client Abraxis BioScience.</li><li>Dewpoint Therapeutics’ $239 million collaboration with Pfizer for the development of new treatments for a rare kind of muscular dystrophy, the $305 million collaboration with Merck on a novel approach for the treatment of HIV, and the up-to-$100 million partnership with Bayer to research new treatments for cardiovascular and gynecological diseases.</li><li>Dewpoint Therapeutics’ partnership with Mitsubishi Tanabe Pharma Corporation, with a deal value up to $480 million and $150 million Series C financing, $77 million Series B financing, and $60 million Series A financing.</li><li>Enveda Therapeutics Inc.’s $130 million raised in Series C financing.</li><li>Frontier Medicines’ $55 million collaboration with AbbVie to develop molecules against hard-to-drug targets.</li><li>Frontier Medicines’ $80 million Series C financing, $88.5 million Series B financing, and Series A Preferred Stock financing of $67 million.</li><li>Indapta Therapeutics’ $22.5 million financing to advance clinical trials of innovative cancer and autoimmune treatments and $50 million Series A financing.</li><li>Johnson & Johnson’s acquisition of TARIS Biomedical, with a focus on transforming the treatment of bladder cancer.</li><li>Lyndra Therapeutics’ $60.5 million Series C financing and $55 million Series B financing.</li><li>Myriad Genetics’ $375 million acquisition of Counsyl, Inc.</li><li>Syntis Bio’s $33 million Series A financing.</li><li>Sonoma Biotherapeutics’ collaboration with Regeneron worth over $100 million.</li><li>The $14 billion acquisition of client Medivation by Pfizer, as well as the previous $225 million Pfizer investment in Medivation.</li><li>The $43 billion acquisition of client Seagen by Pfizer.</li><li>Turnstone Biologics’ acquisition of Myst Therapeutics.</li></ul>

Catherine Polizzi

Karen Potter, Ph.D., J.D., is a nationally recognized patent attorney and leader of Morrison Foerster’s Cell and Gene Therapy Patent practice in San Diego, California. With over 20 years of experience in life sciences intellectual property law, Karen specializes in patent strategy, prosecution, and portfolio management for biotechnology and pharmaceutical companies worldwide.Karen’s technical background in cellular and molecular biology and immunology uniquely positions her as a trusted advisor for innovators in:<ul><li>Cell and gene therapies (including T cell, Natural Killer cell, stem cell, gene-based, and epigenetic therapies)</li><li>Immunotherapies (antibody and protein-based therapies)</li><li>Virus and vaccine therapies</li><li>Companion diagnostics and diagnostic assays</li><li>Protein therapeutics and bioassays</li></ul>Karen leads and mentors a multidisciplinary team of patent attorneys, agents, and scientific analysts, delivering strategic and comprehensive intellectual property services. Her practice includes:<ul><li>U.S. and international patent preparation and prosecution</li><li>Patent portfolio development and management</li><li>Patentability and freedom-to-operate analyses</li><li>Patent term extension strategies</li><li>Due diligence for investors and M&A transactions</li><li>Strategic counseling for startups, emerging, and established life sciences companies</li></ul>Karen is widely recognized for her ability to deliver pragmatic, creative patent solutions tailored to the unique needs of life sciences clients. She has been honored by publications for her leadership and innovative approach in biotechnology patent law.Before her legal career, Karen completed postdoctoral research at the La Jolla Institute for Allergy and Immunology and earned her Ph.D. in cellular and molecular biology from Duke University. Her scientific research has been published in leading peer-reviewed journals and presented at national conferences.

Karen Potter

Shannon Reaney, Ph.D., is a seasoned patent attorney with over 20 years of experience specializing in life sciences intellectual property law. As chair of the firm’s 100+ person Patent Strategy + Prosecution practice and co-chair of the cross-disciplinary Intellectual Property Group, Shannon provides strategic patent counsel to pharmaceutical, biotechnology, cosmetics, and agricultural companies worldwide. She excels in patent portfolio development, prosecution, and management, helping innovators protect and maximize the value of their intellectual property assets.Shannon’s advanced scientific training and extensive legal experience enable her to deliver comprehensive patent strategy and prosecution services across a broad spectrum of life sciences technologies, including:<ul><li>Pre-clinical and clinical-stage therapeutics, including small molecules, siRNA, peptide therapeutics, conjugates, blood-based therapies, and related diagnostics, pharmaceutical formulations, and methods of use.</li><li>Nanotechnology.</li><li>Skin care technology and topical formulations.</li><li>Agricultural technologies.</li></ul>In addition to her extensive experience in patent strategy and prosecution, Shannon is highly regarded for her work in:<ul><li>Patent term extensions & lifecycle management for approved drugs and biologics.</li><li>IP risk mitigation, pre-litigation portfolio assessments, and competitor IP evaluation.</li><li>Due diligence and strategic counseling for business transactions including financings and M&A.</li></ul>Shannon received her Ph.D. in chemistry from the University of California, Santa Cruz, where her doctoral research concentrated on synthetic organic methodology and the use of lithium aminoborohydrides in novel hydride and amine transfer reactions. She received her B.A. in biochemistry from Occidental College, where she conducted undergraduate research investigating psoralen-DNA intercalation.Shannon has authored several first-author publications in peer-reviewed journals and presented her research at major conferences, including those sponsored by the American Chemical Society and the IUPAC World Chemistry Congress.

Shannon Reaney

Michael (Mike) Ward is co-chair of the firm's Life Sciences + Healthcare Group, Intellectual Property Group, and Food + Agriculture Group.Life SciencesFor his work across the life sciences sector, Mike was named San Francisco Biotechnology Lawyer of the Year by Best Lawyers in America in 2020 and is recommended for his patent strategy and prosecution practice in LMG Life Sciences. He also led the team that was named 2022 Patent Management and Strategy Firm of the Year at the 2022 LMG Life Sciences Americas Awards.Food + AgricultureRecognized as “one of the world’s foremost plant and agriculture IP lawyers,” Mike manages a wide range of intellectual property issues related to plants and plant products. He and his team advise clients on plant and plant utility patents; licensing agreements for plant IP; litigation in U.S. state and federal court and before the International Trade Commission; and regulatory approvals from the USDA, FDA, and EPA for gene edited and genetically engineered plants.Patent Strategy + ProsecutionMike is a Legal 500 US Hall of Fame lawyer for patent prosecution and is consistently named one of the leading IP lawyers by Managing Intellectual Property, Chambers USA and Chambers Global, and IAM Patent 1000.Mike works closely with many clients to develop and manage their patent portfolios. He helps clients identify, monitor, and assess the infringement risks of third-party patents. He also assists clients in preparing both offensive and defensive patent portfolios, with a particular emphasis on drafting patent applications that will be utilized in licensing and in litigation efforts.IP Due DiligenceFor venture capitalists seeking to invest in early- and mid-stage companies, underwriters involved in IPOs, and companies seeking to acquire or merge with other companies, Mike has managed extensive IP diligence. His work includes assessment of the strengths and weaknesses of patent portfolios, evaluation of freedom to operate issues, and strategic recommendations for maximizing the value of patent portfolios going forward.Mike also works closely with the IP Litigation Group on various litigation matters including patent interferences to determine the first-to-invent and patent re-examination work and actively participates in both mediation and arbitration proceedings on behalf of clients in the life sciences and food and agriculture areas.He is a frequent lecturer and speaker. Among numerous speaking engagements, Mike is the IP instructor at the UC Davis Licensing Academy and founded Morrison Foerster’s annual Harvard Biotechnology Club Fall Patent Law Course.Mike holds a Ph.D. in plant physiology (biochemistry) and an M.S. in agronomy from the University of California, Davis; a B.S. in biology from the University of California, Berkeley; and a J.D. from Golden Gate University School of Law. He was a post-doctoral fellow in plant molecular biology at the Harvard Medical School and the Department of Molecular Biology at Massachusetts General Hospital, where he worked on the Arabidopsis genome project.

Michael Ward

Dr. Janet (Jian) Xiao is a leading patent attorney specializing in global patent procurement, patent portfolio management, and IP strategic planning for life sciences and biopharmaceutical companies. Recognized by Chambers USA and Chambers Global as a top-ranked intellectual property lawyer, Dr. Xiao is highly sought after by biotech and pharmaceutical innovators worldwide for patent prosecution, patent strategy, and life sciences IP counsel.Dr Xiao’s clients range from large renowned multinational companies to emerging startups worldwide. She advises her clients on patent matters relating to various technologies including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized for her deep understanding of the industry and knowledge of IP, Janet is known for developing and strengthening her clients’ complex patent portfolios to maximize their commercial value and success. She has been instrumental on the strategy development for multibillion-dollar patent portfolios for pharmaceutical clients, and adds tremendous value by combining her creative legal skills, keen business acumen, and solid foundation in science. As impressed clients noted to Chambers, “Janet consistently delivers a very high level of client service and exhibits strong commercial awareness and vision.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, as well as marketing and manufacturing clearance for biopharmaceutical products. She works closely with her clients to assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is most notable for her deep knowledge about patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works synergistically with patent litigators in the event of legal challenges by third-party competitors or vice versa, and is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. As Chambers Global 2024 notes, “She is great, very strong and thoughtful. She has a very large contingent of Chinese companies.”Janet is the Head of China Life Sciences at Morrison Foerster and served as co-chair of the firm’s global Life Sciences Group from 2016 to 2019. Chambers Global states that Janet “is recognized for her knowledge of IP law relating to the life sciences arena,” and that she is “held in high regard by sources for her deep understanding of the pharmaceutical and biotech industries.” In a recent edition of Chambers Global, a client remarks, “Janet is a wonderful lawyer. She is very experienced in advising life sciences clients doing business in China and the US. She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。